MedTrace Logo

CYTO Reductive Surgery in Kidney Cancer Plus Immunotherapy and Targeted Kinase Inhibition

NCT04322955 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 48

Last updated 2025-04-25

No results posted yet for this study

Summary

The purpose of this study is to determine if the use of immunotherapy nivolumab and the targeted therapy cabozantinib prior to removal of the kidney, will increase the number subjects who are without any visible kidney cancer in their body at some point during the course of treatment.

Conditions

Interventions

DRUG

Cabozantinib

2 x 20 mg capsules taken orally daily

DRUG

Nivolumab

480mg IV on first day of each 28-day cycle

PROCEDURE

Cytoreductive nephrectomy

Surgery removing as much tumor tissue as possible, possibly including surrounding tissues.

Sponsors & Collaborators

Principal Investigators

  • Mark N Stein, MD · Associate Professor of Medicine Division of Hematology/Oncology

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-06-22
Primary Completion
2027-05-31
Completion
2028-02-29
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04322955 on ClinicalTrials.gov